VIC Regimen (Vemurafenib/Irinotecan/Cetuximab) Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Unresectable or Metastatic Colorectal Cancer in Asian Patients: A Prospective Cohort Study
Titel:
VIC Regimen (Vemurafenib/Irinotecan/Cetuximab) Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Unresectable or Metastatic Colorectal Cancer in Asian Patients: A Prospective Cohort Study
Auteur:
Chen, Yijiao Zhu, Dexiang Yu, Yiyi Chang, Wenju Ye, Lechi Feng, Qingyang Xu, Pingping Chen, Miao Ji, Meiling Wei, Ye Liu, Tianshu Xu, Jianmin